Safety-by-design as a governance problem
Source abstract
Abstract
Abstract Developments in nanotechnology oblige technology regulators and other stakeholders to manage unfamiliar and unpredictable human health and environmental risks. When technological achievement stretches the limits of understanding of risk and safety, the desire to ensure protection can produce unnecessarily prohibitive and costly regulatory policy. This lack of knowledge, referred within this paper as ‘governance gaps,’ requires safety-by-design to overcome lingering governance challenges. However, the fundamentals of safety-by-design are not developed. We propose translating the methodological framing of safety-by-design and related nanotechnology risk governance into a mathematical framing of Multi-Criteria Decision Analysis (MCDA) to illustrate how safety-by-design might be operationalized. This framing provides a more thorough understanding of technology governance gaps and can help focusing technology development on implementable and safe alternatives. Ultimately, addressing each governance gap can help technology development and technology risk governance keep pace with one another, thereby allowing innovation to flourish while protecting society from undue risks.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Sustainable Supply Chain Management · Health Systems, Economic Evaluations, Quality of Life
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Nano risk governance: current developments and future perspectives
2. The growing gap between emerging technologies and the law
3. Properly paced? Examining the past and present governance of GMOs in the United States
4. Oye · 2012
5. Innovative and responsible governance of nanotechnology for societal development
6. Implementation of safe-by-design for nanomaterial development and safe innovation: why we need a comprehensive approach10.3390/nano8040239 ↗
7. Schwarz-Plaschg · 2017
8. A methodological safe-by-design approach for the development of nanomedicines10.3389/fbioe.2020.00258 ↗
9. Perspectives on the design of safer nanomaterials and manufacturing processes10.1007/s11051-015-3152-9 ↗
10. Malloy · 2016
11. Hodson · 2019
12. What can nanosafety learn from drug development? The feasibility of “safety by design”10.1080/17435390.2017.1299891 ↗
13. Savolainen · 2013
14. Allison · 1971
15. Florin · 2018
16. Emerging health technologies: informing and supporting health policy early10.1016/j.healthpol.2008.01.002 ↗
17. Identifying the science and technology dimensions of emerging public policy issues through horizon scanning10.1371/journal.pone.0096480 ↗
18. Foresight study on the risk governance of new technologies: the case of nanotechnology10.1111/risa.12470 ↗
19. For nanotechnology decisions, use decision analysis10.1016/j.nantod.2012.10.002 ↗
20. A framework and pilot tool for the risk-based prioritization and grouping of nano-enabled consumer products10.1039/C8EN00848E ↗
21. Society for risk analysis glossary
22. Innovation-friendly regulation: the sunset of regulation, the sunrise of innovation
23. Fast science and sluggish policy: the herculean task of regulating biodiscovery10.1016/j.tibtech.2017.09.002 ↗
24. Assessing the protection of the nanomaterial workforce10.3109/17435390.2015.1132347 ↗
25. Treating nanoparticles with precaution: recognising qualitative uncertainty in scientific risk assessment
26. Integrate life-cycle assessment and risk analysis results, not methods10.1038/nnano.2017.152 ↗
27. Risk associated with engineered nanomaterials: different tools for different ways to govern10.1016/j.nantod.2018.03.002 ↗
28. Issues for and examples of computational design of “safe-by-design” nanomaterials
29. E.F.S. Authority (EFSA) · 2019 · 16 · 1626E
30. Advanced tools for the safety assessment of nanomaterials10.1038/s41565-018-0185-0 ↗
31. A one health approach to managing the applications and implications of nanotechnologies in agriculture10.1038/s41565-019-0460-8 ↗
32. Regulatory status of nanotechnologies in food in the EU
33. Kaiser · 2009
34. Kelemen · 2011
35. Linkov · 2009
36. Community-driven hypothesis testing: a solution for the tragedy of the anticommons10.1111/risa.12860 ↗
37. Coalitions, science, and belief change: comparing adversarial and collaborative policy subsystems10.1111/j.1541-0072.2009.00310.x ↗
38. Brady · 2005
39. Regulation and regime: the comparative politics of adaptive regulation in synthetic biology10.1007/s11077-019-09356-0 ↗
40. Nanotechnology and the need for risk governance10.1007/s11051-006-9092-7 ↗
41. Linkov · 2020
42. Correlative stimulated emission depletion and scanning ion conductance microscopy10.1021/acsnano.8b01731 ↗
43. Jasanoff · 2004